FDA policy 'suportive' of Ocular Therapeutix (OCUL) Axpaxli NDA Submission on SOL-1 Alon - Raymond James
Tweet Send to a Friend
Raymond James analyst Sean McCutcheon reiterated a Strong Buy rating and $28.00 price target on Ocular Therapeutix (NASDAQ: OCUL), noting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
